Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

References

• Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019;30(5):706–8. doi:10.1093/annonc/mdz056.
   PubMed Web of Science ®Google Scholar
• Giuliano S, Cormerais Y, Dufies M, Grépin R, Colosetti P, Belaid A, Parola J, Martin A, Lacas-Gervais S, Mazure NM, et al. Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux. Autophagy. 2015;11(10):1891–1904. doi:10.1080/15548627.2015.1085742.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2018;378(14):1277–1290. doi:10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 2019;380(12):1103–1115. doi:10.1056/NEJMoa1816047.
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263–274. doi:10.1038/nrc1586.
   PubMed Web of Science ®Google Scholar
• Kahlmeyer A, Stöhr CG, Hartmann A, Goebell PJ, Wullich B, Wach S, Taubert H, Erlmeier F. Expression of PD-1 and CTLA-4 are negative prognostic markers in renal cell carcinoma. JCM. 2019;8(5):743. doi:10.3390/jcm8050743.
   Google Scholar
• Chipollini J, da Costa WH, Werneck da Cunha I, de Almeida E Paula F, Salles P GO, Azizi M, Spiess PE, Abreu D, Zequi S de C. Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies. Ther Adv Urol. 2019;11:175628721988260. doi:10.1177/1756287219882600.
   Web of Science ®Google Scholar
• Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, Cheung CC, Chung J-H, Couture C, Fiset PO, et al. “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod Pathol. 2020;33(1):4–17. doi:10.1038/s41379-019-0327-4.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yin X, Zhang H, Sun G, Yang Y, Chen J, Zhu X, Zhao P, Zhao J, Liu J, et al. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. BMC Cancer. 2019;19(1):360. doi:10.1186/s12885-019-5578-4.
   PubMedGoogle Scholar
• Zhu X, Soluble LJ. PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. 2017;8(57):97671–97682. doi:10.18632/oncotarget.18311.
   PubMedGoogle Scholar
• Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, et al. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers. 2020;12(2):473. doi:10.3390/cancers12020473.
   PubMed Web of Science ®Google Scholar
• Aghajani MJ, Roberts TL, Yang T, McCafferty CE, Caixeiro NJ, DeSouza P, Niles N. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer. Endocrine Connections. 2019;8(7):1040–1051. doi:10.1530/EC-19-0210.
   PubMed Web of Science ®Google Scholar
• Gu D, Ao X, Yang Y, Chen Z, Xu X. Soluble immune checkpoints in cancer: production, function and biological significance. J Immunotherapy Cancer. 2018;6(1):132. doi:10.1186/s40425-018-0449-0.
   PubMedGoogle Scholar
• Li Y, Cui X, Yang Y-J, Chen -Q-Q, Zhong L, Zhang T, Cai R-L, Miao J-Y, Yu S-C, Zhang F. Serum sPD-1 and sPD-L1 as biomarkers for evaluating the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients. Clin Breast Cancer. 2019;19(5):326–332.e1. doi:10.1016/j.clbc.2019.03.008.
   PubMed Web of Science ®Google Scholar
• Theodoraki M-N, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1 + exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24(4):896–905. doi:10.1158/1078-0432.CCR-17-2664.
   PubMed Web of Science ®Google Scholar
• Cho I, Lee H, Yoon SE, Ryu KJ, Ko YH, Kim WS, Kim SJ. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer. 2020;20(1):120. doi:10.1186/s12885-020-6612-2.
   PubMed Web of Science ®Google Scholar
• Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res. 2017;5(6):480–492. doi:10.1158/2326-6066.CIR-16-0329.
   PubMed Web of Science ®Google Scholar
• Park H, Bang J-H, Nam A-R, Eun Park J, Hua Jin M, Bang Y-J, Oh D-Y. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Sci Rep. 2019;9(1):11131. doi:10.1038/s41598-019-47330-1.
   PubMedGoogle Scholar
• Bian B, Fanale D, Dusetti N, Roque J, Pastor S, Chretien A-S, Incorvaia L, Russo A, Olive D, Iovanna J. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. OncoImmunology. 2019;8(4):e1561120. doi:10.1080/2162402X.2018.1561120.
   PubMed Web of Science ®Google Scholar
• Buderath P, Schwich E, Jensen C, Horn PA, Kimmig R, Kasimir-Bauer S, Rebmann V. Soluble programmed death receptor ligands sPD-L1 and sPD-L2 as liquid biopsy markers for prognosis and platinum response in epithelial ovarian cancer. Front. Oncol. 2019;9:1015. doi:10.3389/fonc.2019.01015.
   PubMed Web of Science ®Google Scholar
• Chang B, Huang T, Wei H, Shen L, Zhu D, He W, Chen Q, Zhang H, Li Y, Huang R, et al. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68(3):353–363. doi:10.1007/s00262-018-2271-4.
   PubMed Web of Science ®Google Scholar
• Sorensen SF, Demuth C, Weber B, Sorensen BS, Meldgaard P. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib. Lung Cancer. 2016;100:77–84. doi:10.1016/j.lungcan.2016.08.001.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Kamai T, Masuda A, Nukui A, Abe H, Arai K, Yoshida K-I. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Cancer Med. 2016;5(8):1810–1820. doi:10.1002/cam4.754.
   PubMed Web of Science ®Google Scholar
• Kushlinskii NE, Gershtein ES, Morozov AA, Goryacheva IO, Filipenko ML, Alferov AA, Bezhanova SD, Bazaev VV, Kazantseva IA. Soluble ligand of the immune checkpoint receptor (sPD-L1) in blood serum of patients with renal cell carcinoma. Bull Exp Biol Med. 2019;166(3):353–357. doi:10.1007/s10517-019-04349-8.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang J, Tu H, Liang D, W CD, Ye Y, Wu X. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients. J Immunotherapy Cancer. 2019;7(1):334. doi:10.1186/s40425-019-0810-y.
   PubMed Web of Science ®Google Scholar
• Yao J-X, Chen X, Xi W, Zhu Y-J, Wang H, Hu X-Y, Guo J-M. Immunoscore system for predicting clinical outcome of metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. J. Cancer. 2018;9(22):4099–4107. doi:10.7150/jca.27408.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, Giraldo N, Rioux-Leclercq N, Molinié V, Sibony M, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res. 2015;21(6):1329–1339. doi:10.1158/1078-0432.CCR-14-1128.
   PubMed Web of Science ®Google Scholar
• Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, et al. An immune atlas of clear cell renal cell carcinoma. Cell. 2017;169(4):736–749.e18. doi:10.1016/j.cell.2017.04.016.
   PubMed Web of Science ®Google Scholar
• Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, et al. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. J Immunotherapy Cancer. 2019;7(1):139. doi:10.1186/s40425-019-0621-1.
   PubMed Web of Science ®Google Scholar
• Mella M, Kauppila JH, Karihtala P, Lehenkari P, Jukkola-Vuorinen A, Soini Y, Auvinen P, Vaarala MH, Ronkainen H, Kauppila S, et al. Tumor infiltrating CD8 + T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma. OncoImmunology. 2015;4(6):e1002726. doi:10.1080/2162402X.2014.1002726.
   PubMed Web of Science ®Google Scholar